In the AWARD-7 trial, which included patients with T2DM and chronic kidney disease, treatment with dulaglutide compared to insulin resulted in a lower rate of GFR reduction or end-stage renal disease, particularly in those with macroalbuminuria [94]. Here, INS is linked to type 2 diabetes mellitus.